Screening 3.4 million newborns for primary carnitine deficiency in Zhejiang Province, China

Yiming Lin,Hao Xu,Duo Zhou,Zhenzhen Hu,Chao Zhang,Lingwei Hu,Yu Zhang,Lin Zhu,Bin Lu,Ting Zhang,Xinwen Huang
DOI: https://doi.org/10.1016/j.cca.2020.04.039
IF: 6.314
2020-08-01
Clinica Chimica Acta
Abstract:<p>Testing for primary carnitine deficiency (PCD) has been implemented in many newborn screening (NBS) programs, but few large-scale studies on NBS for PCD have been reported in China. This study aimed to assess the incidence and biochemical, clinical, and genetic characteristics of PCD discovered by NBS. Dried blood spots from newborns were analyzed by tandem mass spectrometry (MS/MS) and suspected positive patients were further tested using molecular genetic analysis. Infants who carried two variants in <em>SLC22A5</em> or those with extremely low free carnitine levels during recall were referred for follow-up and treatment. Over 3.4 million newborns were screened and 113 newborns were diagnosed with PCD, yielding a positive predictive value of 1.93%. In addition, 63 mothers with PCD were identified. The incidence of PCD in newborns and mothers in Zhejiang was 1:30,182 and 1:54,137, respectively. Thirty-seven distinct variants were identified in <em>SLC22A5</em> of which 10 were novel. c.1400C&gt;G (p.S467C) was the most prevalent variant in both newborns and mothers with PCD, while c.760C&gt;T (p.R254*), which is reportedly common in other Chinese regions, was rarely detected in maternal PCD patients. This study reports the largest series of patients with PCD detected by NBS and identifies 10 novel variants, expanding the variant spectrum of <em>SLC22A5</em>.</p>
medical laboratory technology
What problem does this paper attempt to address?